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To the Editor:
We read with interest Joshita and colleagues' letter regarding our original article [1] .
In taking the time to present their important Japanese data [2] , the authors provide further independent validation of AST/platelet ratio (APRI) in risk stratification of patients with primary biliary cirrhosis (PBC). As the authors surmise, whilst the demography of our cohorts was varied it was not representative of all populations globally, and the robustness of any observation -even if simple and low cost as in this case -is in validation more so than discovery.
PBC is not a benign, homogeneous autoimmune liver disease; and although present disease nomenclature needs improvement, the current sole therapy -ursodeoxycholic 
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